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In South Africa, the Expanded Programme of Immunisation
(EPI) recommends measles vaccination at 9 and 18 months.
Measles mumps rubella (MMR) combination vaccines are not
included in this regimen, but vaccination against rubella is
recommended in females before childbearing age. Reported
national measles vaccine coverage rates have been low over the
previous 5 years (60%), and targets have therefore been set to
improve the EPI coverage rates to 90%. 1 Contributing in part to
the low vaccine coverage are egg-allergic children who are
denied measles or MMR vaccination by health care workers
wishing to avoid potential allergic reactions. It is therefore
appropriate to highlight the recommendations of international
health authorities, which share the local consensus that
immunisations should not be withheld from egg-allergic
patients.2-4 Despite these recommendations, the package inserts
for local vaccines propagated in cultures of fibroblasts from
chick embryos (listed below), continue to highlight egg allergy
as a contraindication to vaccine administration.
Locally available MMR vaccine
products5
Measles vaccines. Four measles vaccines are available:
Diplovax contains the Edmonton Zagreb viral strain and is
propagated on human diploid cells. Morbilivax, Rimevax and
Rouvax are grown in cultures of fibroblasts from chick
embryos and contain the Schwartz viral strain. 
Rubella vaccines. Rudivax is propagated on human diploid
cell cultures.
MMR vaccines. Two of the three locally available MMR
vaccines are grown in cultures of fibroblasts from chick
embryos, namely MMR II and Trimovax. Trivarten Berna
vaccine is propagated on human diploid cells.
All vaccines cultured in cultures from chick embryos contain
minute, if any, egg ovalbumin. An analysis of the MMR II
(MSD) vaccine, found it to contain £ 1 ng ovalbumin per 0.5 ml
dose.6-8 In most double-blind, placebo-controlled challenges for
egg allergy, the minimum oral doses that elicit allergic
reactions are between  50 mg and 100 mg, although
occasionally this may be as low as 2 mg.9 Therefore, the
amount of ovalbumin in the vaccines seems to be too small to
cause an allergic reaction in the majority of individuals even
considering the parenteral route of exposure. Other potential
allergens in the measles vaccine include gelatin and
neomycin;10 both of these agents are present in larger doses
than ovalbumin.11-13 The majority of life-threatening allergic
reactions to MMR vaccine have been reported in children who
are not allergic to eggs. It therefore seems more likely that these
reactions are due to the gelatin or neomycin contained in the
vaccine.
A literature review14 shows that only children with a history
of life-threatening reaction to egg or who have an allergy to
eggs and coexisting asthma had life-threatening reactions after
being vaccinated against measles. Skin prick testing has been
used to try to predict allergic reactions to measles vaccinations,
and there have been attempts to ‘desensitise’ children to egg
using graded injections. Adverse systemic reactions to these
procedures have been reported, and in this scenario, these
procedures lack scientific rationale.14-16 Interpretation of the
Pharmacia Immuno CAP-RAST immunoglobulin E (IgE) test
remains difficult if positive, as predictive cut-off values do not
exist for children with only a suspicion of having egg allergy
with no concomitant atopic disease, e.g. eczema. The negative
result does, however, provide a high negative predictive value
and may allay fears at future vaccination, but this invasive test
should be restricted to those children at high risk, and is
impractical as a screening tool. 
Recommendations
Measles and MMR vaccines are as safe as any other vaccine,
and can safely be given to the vast majority of children
regardless of whether or not they are allergic to eggs. As with
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The small subgroup of children at increased risk, albeit
remote, of experiencing an allergic reaction include:
1. Children with an allergy to eggs in whom previous
exposure (prior oral ingestion or during vaccination) led to
cardiorespiratory reactions. Children who have experienced
milder forms of allergic reactions to eggs can be vaccinated
safely without  additional precautions.
2. Children who have food allergies and active, chronic
asthma.17
This subgroup at increased risk must receive vaccination
under medical supervision in a setting where resuscitation
facilities and an anaphylaxis management protocol are
available. Vital signs should be monitored for 2 hours post
vaccination.18 Any child suspected of having had an allergic
reaction to measles or MMR vaccine should be referred  to a
specialist allergy unit to define the timing and nature of the
reaction and to evaluate the possible allergens involved.
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In recent years, mental illness has been increasingly
acknowledged as a major contributor to morbidity in both the
developed and developing worlds.1 To provide effective mental
health care, practitioners require knowledge of advances in
detection, assessment and treatment based on the best available
evidence. The Internet and advent of electronic publishing
mean that clinicians have access to the latest evidence almost
as soon as new research findings are made. 2 However, the
enormous volume of available information can be
overwhelming for busy practitioners. In an effort to provide
the latest evidence in an accessible format, the Cochrane
Collaboration prepares, updates and disseminates systematic
reviews of the effects of health care interventions. These
reviews attempt to provide answers to health care questions by
identifying and appraising all relevant empirical studies and
synthesising the results.3,4 The reviews are published
electronically on a database, The Cochrane Library. The
psychiatric field is well represented within the Collaboration
and since its inception in 1993, over 130 reviews on psychiatric
topics have been published (www.cochrane.org).
In order to inform proposed evidence-based health care
(EBHC) training workshops specific to mental health
practitioners and to identify appropriate measures of
dissemination to this group, we undertook a survey of South
African psychiatrists and general practitioners (GPs) with a
special interest in mental health regarding their knowledge of,
and attitudes towards, evidence-based mental health care
(EBMHC).
ISSUES IN PRACTICE
What do South African psychiatrists and GPs think, feel 
and know about evidence-based mental health care?
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